NOXXON Pharma Announces New Preclinical Data Showing Synergy of Lead Compound NOX-A12 With Natural Killer (NK) Cell Mediated Therapies
NOXXON Pharma signs clinical immuno-oncology Collaboration Agreement with MSD to study NOX-A12 combined with Keytruda® (Pembrolizumab) in panacreatic and colorectal Cancer